Genmab at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Genmab brings 2 presentations to PEGS Europe 2026 in Lisbon. Its program pairs antibody engineering with large-scale data generation, including a dataset on how VHH binding to antigen holds up across mutations. It also covers T cell stimulating vaccines used to strengthen CD3 bispecific antibody therapy in solid tumours.

OrganizationPEGS Europe 2026 Attendance
Genmab
Copenhagen, Denmark
genmab.com
Biotech
Danish antibody company developing bispecifics and antibody-drug conjugates, with marketed medicines in oncology.
Talk
Wed Nov 18
9:00am–9:30am
Talk
Wed Nov 18
6:01pm–6:30pm
T Cell Stimulating Vaccines Empower CD3 Bispecific Antibody Therapy in Solid Tumours
Advancing Multispecific Antibodies and Combination Therapy to the Clinic

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Genmab

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction